Sovaprevir: Additional Phase IIa data

Data from 36 evaluable patients with chronic HCV genotype 1 infection in the second part of a double-blind, placebo-controlled, U.S. and Belgian Phase IIa trial showed that once-daily oral sovaprevir in combination with standard of care (SOC; peginterferon alfa-2a and ribavirin) for 12 weeks followed by SOC alone for an additional 12 weeks led to an SVR4, defined as undetectable HCV RNA levels (<25 IU/mL) 4 weeks after the end of treatment, in 90% of patients in the 200 mg sovaprevir arm, 85% of patients in the 400 mg sovaprevir arm and 100% of patients in the 800 mg sovaprevir arm. After the initial 12-week treatment period, 39 patients were assigned to receive SOC alone for an additional 12 weeks and 14 were assigned to receive SOC alone for an additional 36 weeks. Achillion expects to report SVR4 and SVR12 data for all patients who received sovaprevir plus SOC for 12 weeks followed by SOC alone for an additional 12 or 36 weeks in 1Q13. ...